A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

Trial Profile

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Dolutegravir/lamivudine (Primary) ; Tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 24 Jul 2018 Planned number of patients changed from 550 to 750.
    • 12 Jul 2018 Planned primary completion date changed from 2 Aug 2019 to 14 Jun 2019.
    • 28 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top